Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...

If you are looking to invest in top growth stocks, these companies can experience more volatility than the average stock.

Novo Nordisk and Eli Lilly's motion to dismiss took aim at most of the counts asserted in the plaintiffs’ master long-form ...

finds that among glucagon-like peptide 1 (GLP-1) receptor agonists and co-agonists on the market or still being investigated, the experimental drug retatrutide (Eli Lilly and Company) produces the ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. The stock is up about 36% year to date as of ...

inhibits β-cell apoptosis and inhibits glucagon secretion. Two such drugs are currently approved — exenatide (Byetta; Amylin/Eli Lilly and Company) and liraglutide (Victoza; NovoNordisk ...

Eli Lilly’s intranasal formulation of glucagon – called Baqsimi – is the first alternative to injectable glucagon for severe hypoglycaemia, which typically occurs when people with diabetes ...